Literature DB >> 14557892

Total cystectomies in the surgical treatment of rectal cancer with prior chemoradiation: analysis of postoperative morbidity and survival.

Janusz Oledzki1, Maciej Chwaliński, Wojciech Rogowski, Rafał Sopyło, Marek P Nowacki.   

Abstract

BACKGROUND AND AIMS: Curative surgery for rectal cancer seldom requires urinary tract resections. The study investigated morbidity and survival following resection of rectum with total cystectomy following chemoradiation for primary rectal cancer. PATIENTS AND METHODS: 19 consecutive patients with primary nonresectable rectal cancer undergoing preoperative chemoradiation and operated on by a multidisciplinary team of surgeons.
RESULTS: Morbidity was moderately low, and only five cases required surgical reintervention. No postoperative deaths were observed. Long-term survival in this group of patients compares well with the survival of patients with primarily nonresectable rectal cancer without the involvement of urinary bladder.
CONCLUSION: Extended pelvic exenteration due to rectal cancer is relatively safe and in selected patients offers long-term survival and a chance of a cure. Involvement of the urinary bladder does not adversely affect outcome of rectal cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557892     DOI: 10.1007/s00384-003-0550-8

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  23 in total

1.  Patterns of recurrence following pelvic exenteration and external radiotherapy for locally advanced primary rectal adenocarcinoma.

Authors:  P Luna-Perez; S Delgado; S Labastida; N Ortiz; D Rodriguez; L Herrera
Journal:  Ann Surg Oncol       Date:  1996-11       Impact factor: 5.344

Review 2.  Aggressive multimodality treatment for locally advanced irresectable rectal cancer.

Authors:  R Farouk; H Nelson; L L Gunderson
Journal:  Br J Surg       Date:  1997-06       Impact factor: 6.939

3.  Outcome of total pelvic exenteration for primary rectal cancer.

Authors:  Hideyuki Ike; Hiroshi Shimada; Shigeki Yamaguchi; Yasushi Ichikawa; Shouichi Fujii; Shigeo Ohki
Journal:  Dis Colon Rectum       Date:  2003-04       Impact factor: 4.585

4.  Total pelvic exenteration: results from a multispecialty team approach to complex cancer surgery.

Authors:  Y H Ho; C Cheng; S K Tay
Journal:  Int Surg       Date:  2001 Apr-Jun

5.  Transureteroureterostomy: an adjunct to the management of advanced primary and recurrent pelvic malignancy.

Authors:  Paul H Sugarbaker; Mordechai Gutman; Mohan Verghese
Journal:  Int J Colorectal Dis       Date:  2002-05-08       Impact factor: 2.571

6.  Total pelvic exenteration with preoperative irradiation for advanced primary and recurrent rectal cancer.

Authors:  Johan N Wiig; Jan P Poulsen; Stein Larsen; Morten Braendengen; Håkon Waehre; Karl-Erik Giercksky
Journal:  Eur J Surg       Date:  2002

7.  Morbidity and mortality following preoperative radiation therapy and total pelvic exenteration for primary rectal adenocarcinoma.

Authors:  P Luna-Perez; D F Rodriguez; D Flores; S Delgado; S Labastida
Journal:  Surg Oncol       Date:  1995       Impact factor: 3.279

8.  Pelvic exenteration: a 15-year experience in a general metropolitan hospital.

Authors:  H E Averette; M Lichtinger; B U Sevin; R E Girtanner
Journal:  Am J Obstet Gynecol       Date:  1984-09-15       Impact factor: 8.661

9.  Pelvic and sacropelvic exenteration for locally advanced or recurrent anorectal cancer.

Authors:  N W Pearlman; R E Donohue; G V Stiegmann; D J Ahnen; S M Sedlacek; T J Braun
Journal:  Arch Surg       Date:  1987-05

10.  Pelvic exenteration for primary and recurrent vulvar cancer.

Authors:  B Miller; M Morris; C Levenback; T W Burke; D M Gershenson
Journal:  Gynecol Oncol       Date:  1995-08       Impact factor: 5.482

View more
  1 in total

1.  Total pelvic exenteration for rectal cancer: outcomes and prognostic factors.

Authors:  Trustin S Domes; Patrick H D Colquhoun; Brian Taylor; Jonathan I Izawa; Andrew A House; Patrick P W Luke; Jonathan I Izawa
Journal:  Can J Surg       Date:  2011-12       Impact factor: 2.089

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.